Andrew M Tershakovec

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1982898/publications.pdf

Version: 2024-02-01

933447 1372567 10 679 10 10 citations g-index h-index papers 10 10 10 815 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis. Atherosclerosis, 2014, 237, 829-837.	0.8	32
2	Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population. American Heart Journal, 2014, 168, 205-212.e1.	2.7	93
3	Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. Journal of Clinical Lipidology, 2014, 8, 107-116.	1.5	31
4	Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. Vascular Health and Risk Management, 2013, 9, 719.	2.3	28
5	Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis, 2012, 223, 251-261.	0.8	203
6	Safety and Efficacy of Ezetimibe Added on to Rosuvastatin 5 or 10 mg Versus Up-Titration of Rosuvastatin in Patients With Hypercholesterolemia (the ACTE Study). American Journal of Cardiology, 2011, 108, 523-530.	1.6	59
7	Safety and Efficacy of Ezetimibe Added to Atorvastatin Versus Up Titration of Atorvastatin to 40 mg in Patients ≥65 Years of Age (from the ZETia in the ELDerly [ZETELD] Study). American Journal of Cardiology, 2010, 105, 656-663.	1.6	45
8	Update on the efficacy and safety of combination ezetimibe plus statin therapy. Clinical Lipidology, 2010, 5, 655-684.	0.4	33
9	(to 40 mg) in Hypercholesterolemic Patients at Moderately`High Risk for Coronary Heart Diseaseã€ã€Conflicts of interest: Dr. Conard served as a consultant and advisor for Merck & Company and Merck/Schering-Plough. Dr. Bays received research grants from Amylin, San Diego, California, Amgen, Thousand Oaks, California, I&I, Langhorne, Pennsylvania, Aegerion.	1.6	75
10	Efficacy and Safety of Ezetimibe Added on to Atorvastatin (40 mg) Compared With Uptitration of Atorvastatin (to 80 mg) in Hypercholesterolemic Patients at High Risk of Coronary Heart Disease. American Journal of Cardiology, 2008, 102, 1495-1501.	1.6	80